3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Pathologic Complete Response
1
Neoplasms
1
Hemangiosarcoma
1
Breast Neoplasms
1
Interventions
pembrolizumab
90
Blood Specimen Collection
41
Cyclophosphamide
37
Bevacizumab
36
Nivolumab
34
Standard of Care
32
Carboplatin
32
Surveys and Questionnaires
29
Paclitaxel
27
atezolizumab
25
Exercise
25
Pemetrexed
24
Cisplatin
24
Gemcitabine
23
Fluorouracil
22
Radiotherapy
20
Leucovorin
20
Dexamethasone
20
Oxaliplatin
18
Docetaxel
18
Rituximab
16
Irinotecan
16
Cetuximab
16
Drug Therapy
15
Doxorubicin
15
dostarlimab
14
Biopsy
14
130-nm albumin-bound paclitaxel
14
fludarabine
13
Prednisone
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
patritumab
×
1 year
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled